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2646 | Food Funct., 2014, 5, 2646–265interactions and inhibition of
glycation – combining a systematic review and
experimental models for enhanced physiological
relevance
A. Vlassopoulos, M. E. J. Lean and E. Combet*
Background: while antiglycative capacity has been attributed to (poly)phenols, the exact mechanism of
action remains unclear. Studies so far are often relying on supra-physiological concentrations and use of
non-bioavailable compounds. Methods: to inform the design of a physiologically relevant in vitro study,
we carried out a systematic literature review of dietary interventions reporting plasma concentrations of
polyphenol metabolites. Bovine Serum Albumin (BSA) was pre-treated prior to in vitro glycation: either
no treatment (native), pre-oxidised (incubated with 10 nM H2O2, for 8 hours) or incubated with a mixture
of phenolic acids at physiologically relevant concentrations, for 8 hours). In vitro glycation was carried
out in the presence of (i) glucose only (0, 5 or 10 mM), (ii) glucose (0, 5 or 10 mM) plus H2O2 (10 nM), or
(iii) glucose (0, 5 or 10 mM) plus phenolic acids (10–160 nM). Fructosamine was measured using the
nitro blue tetrazolium method. Results: following (high) dietary polyphenol intake, 3-hydroxyphenylacetic
acid is the most abundant phenolic acid in peripheral blood (up to 338 mM) with concentrations of other
phenolic acids ranging from 13 nM to 200 mM. The presence of six phenolic acids with BSA during in
vitro glycation did not lower fructosamine formation. However, when BSA was pre-incubated with
phenolic acids, signiﬁcantly lower concentration of fructosamine was detected under glycoxidative
conditions (glucose 5 or 10 mM plus H2O2 10 nM) (p < 0.001 vs. native BSA). Conclusion: protein pre-
treatment, either with oxidants or phenolic acids, is an important regulator of subsequent glycation in a
physiologically relevant system. High quality in vitro studies under conditions closer to physiology are
feasible and should be employed more frequently.Introduction
Protein glycation has been implicated in the development of
several chronic diseases, particularly diabetic micro and mac-
rovascular complications.1,2 The process of glycation, in dia-
betes, is mainly driven by the elevated blood glucose
concentration through non-enzymatic condensation of a sugar
molecule on a protein, lipid or DNA molecule.3,4 Measurement
of glycated haemoglobin is the standard method for monitoring
diabetes control5 and elevated levels are clearly related to tissue
damage. Glycated albumin levels in plasma can vary widely,
between 1% to up to 16% in normoglycemic individuals6,7 and
the reasons for this wide range are not fully understood. In
individuals free of diabetes a 30–50% higher risk of cardiovas-
cular disease is suggested for every one unit higher HBA1c
(%).8–10 Although in vitro studies have been employed to study
glycation mechanisms, few have used physiologically relevantge of Medical, Veterinary & Life Sciences,
. E-mail: Emilie.CombetAspray@glasgow.
0)141 201 0768
5glucose concentrations. In vitro protein glycation does not easily
occur with physiological concentrations of glucose, implying
that another factor was necessary. We recently demonstrated
that albumin glycation at physiological glucose concentrations
(5 and 10 mM) was driven by oxidative stress, and that oxidised
albumin is more susceptible to glycation than the native form of
the protein.11 We have suggested that the reaction might be
considered protein glycoxidation, rather than simply glycation.
The study of early glycation, using fructosamine, is of impor-
tance for the translational value of the model (HbA1c is
commonly used in clinical practice). As the rst stable glycation
product, its production rate is inuential on total AGEs
production.12
Antioxidants, and (poly)phenols and their metabolites in
particular, have been studied for their in vitro antiglycative
properties.13–17 (Poly)phenols may oﬀer protection by scav-
enging ROS produced during the glycation reaction, thereby
slowing glycation and inhibiting the formation of AGEs.13,18
Another possible mechanism involves “physical” protection
against glycation. This mechanism suggests that (poly)phenols
have the capacity to bind to the protein molecule, most likelyThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinewith a non-covalent bond, and in this way make glycation
targets on the protein molecule (usually amino acids like lysine)
inaccessible to take part in the glycation reaction.19,20
While these studies may hold value in food science (for
example, reduction of AGE formation during cooking in the
presence of polyphenols21), their physiological relevance to
human health is sometimes questionable. (Poly)phenols are
subject to extensive metabolism in the lumen (hydrolysis by the
enterocytes' glucosidase system) and aer absorption (glucur-
onidation/sulfation in the liver).22,23Most highmolecular weight
dietary polyphenols have low bioavailability and even though
aglycones may reach systemic circulation in small amounts,
glycosides do not.23–26 Those which do not get absorbed instead
accumulate in the colon lumen, where they are subject to
bacterial degradation, leading to the formation of phenolic
acids. Phenolic acids have a relatively higher bioavailability.22,27
In plasma, an increase in phenolic acid levels is seen 8–10 hours
aer ingestion, which represents the ‘colonic tide’ of (poly)
phenol metabolites.22,28,29 Studies using foodstuﬀ extracts and
mixtures containing aglycones and glycosides thus do not
replicate physiology25,30 when (poly)phenols in the circulation
are mostly phase II metabolites and rarely exceed the 1 mM
concentration (and if so, transiently).27,28 Finally, while single
compound studies are informative and allow for mechanisms of
action to be dissected, polyphenols and their metabolites are
not found or consumed in isolation;23,31 they are, also, all
consumed within complex food matrices with other nutrients
that may modify absorption and metabolism.32,33
The present paper systematically reviews the literature
reporting plasma levels of phenolic acids as key polyphenol
metabolites, following ingestion of polyphenol rich food prod-
ucts (not under “acute” trial settings). The outcomes of this
review are then used to test whether phenolic acids can inhibit
the early stages of glycation under physiologically relevant
experimental conditions, using the bench-top design we previ-
ously described.11Fig. 1 Experimental design for the study of the antiglycative potential
of physiologically relevant phenolic acids. BSA: bovine serum albumin,
ox-BSA: bovine serum albumin incubated with 10 nM H2O2, PP-BSA:
bovine serum albumin incubated with phenolic acid mixtures; PP:
caﬀeic acid 10 nM, p-coumaric acid 8 nM, vanillic acid 21 nM, proto-
catechuic acid 40 nM, 3-hydroxyphenyl acetic acid 160 nM and 3,4-
dihydroxyphenyl acetic acid 40 nM.Material and methods
Systematic literature review
This review was conducted following the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA)
guidelines. A literature study was carried out in PubMed® and
ISI Web of Knowledge® for trials reporting plasma phenolic
acid levels aer a high polyphenol food/diet intake. The search
was inclusive of all years up to February 2014. The following
search terms were used to identify relevant studies: (phenol*,
polyphenol*, phenolic acid*, fruit, vegetable, spice, cocoa, herb,
juice, oil, wine, extract, tea or coﬀee), paired (bolean AND) with
(feeding, trial, intervention, consumption OR supplementa-
tion). The wild-card term “*” was used to improve the sensitivity
of the search by increasing the number of matches. The review
was limited to studies utilising chromatographic techniques to
identify (poly)phenolic compounds in serum or plasma. Studies
on animals were excluded, as well as studies reporting cross-
sectional data. Only controlled long-term feeding trials wereThis journal is © The Royal Society of Chemistry 2014reviewed. Studies were included in the review if absolute
concentrations of phenolic acids were reported.Experimental procedures
Chemicals. Bovine serum albumin (BSA), sodium azide,
nitro blue tetrazolium, D-glucose, PBS, 1-deoxy-1-morpholino-
fructose (DMF), hydrogen peroxide, caﬀeic acid, p-coumaric
acid, vanillic acid, 3-hydroxyphenylacetic acid, 3,4-dihydroxy-
phenylacetic acid and protocatechuic acid were purchased from
Sigma-Aldrich (Dorset, UK). SnakeSkin Dialysis Tubing, 3.5 K
MWCO, was purchased from Thermo Fisher Scientic (Not-
tinghamshire, UK).
Albumin pre-treatment. BSA (40 g L1) was studied in three
diﬀerent forms: native BSA (BSA), pre-oxidised BSA (ox-BSA),
and phenolic acid-pre-incubated BSA (PP-BSA). Ox-BSA was
incubated with 10 nM hydrogen peroxide (H2O2) for 8 h pre-
glucose incubation and PP-BSA was incubated with a phenolic
acid mixture for 8 h pre-glucose incubation. The phenolic acids
used were selected based on the results of the literature review
aiming to be a representative of plasma concentrations of free
phenolic acids, with a higher degree of physiological relevance.
The acids and concentrations used were: caﬀeic acid 10 nM, p-
coumaric acid 8 nM, vanillic acid 21 nM, protocatechuic acid 40
nM, 3-hydroxyphenyl acetic acid 160 nM and 3,4-dihydroxy-
phenyl acetic acid 40 nM. Following pre-treatment, ox-BSA and
PP-BSA were dialysed against PBS for 24 h to remove any free
H2O2 and/or phenolic acids (Fig. 1).
Protein glycation. All incubation processes took place in PBS
(0.137 M Sodium chloride, 0.0027 M potassium chloride, and
0.010 M phosphates) with sodium azide (0.2 g L1), in a nal
volume of 1.5 mL, for 14 days. BSA, ox-BSA and PP-BSA (40 g L1)
were incubated with glucose (0, 5, 10 mM) with or without 10
nM H2O2 or a physiologically relevant phenolic acid mix (as
described above). All incubations were replicated 6 times
(Fig. 1).Fructosamine measurement
Fructosamine levels were measured at week 2 with the NBT
assay, performed in microplates as described previously.34
Briey, samples (30 mL) were added to sodium carbonate buﬀer
(100 mL, 100 mM, and pH 10.8) with nitro blue Tetrazolium
(0.25 mM). Microplates were incubated for 15 min at 37 C andFood Funct., 2014, 5, 2646–2655 | 2647
Fig. 2 Flow diagram of the study selection process.
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View Article Onlinemeasured spectrophometrically against controls at 550 nm aer
10 and 15 min of incubation. The diﬀerence between the two
readings was used to calculate concentrations. The fructos-
amine analog 1-deoxy-1-morpholinofructose (DMF) was used as
a standard. All fructosamine measurements were performed in
duplicate. The potential interference of H2O2 and phenolic
acids with NBT colorization was tested, with no evidence of
interference detected. Standards and NBT reagents were made
fresh every week and stored at 20 C and 4 C, respectively. All
samples were stored at 20 C prior to assay.Measurement of AGE uorescence
AGE uorescence was measured in diluted samples (1 : 5) at an
excitation wavelength of 370 nm and an emission wavelength of
440 nm. AGE uorescence was measured as arbitrary units and
in duplicate using a SpectraMax M2 plate reader.Protein structure analysis
Protein tryptophan uorescence intensity was recorded with a
Shimadzu RF-5301 PC Spectrouorophotometer, using 5 nm
excitation and 10 nm emission slit widths. Proteins at a
concentration of 0.2 g L1 in PBS were used aer dialysis and
prior to glycation. The UV spectra of the protein, recorded using
a Perkin Elmer Lambda 25 UV/VIS Spectrometer, indicated a
maximum absorbance at 277 nm for all proteins, which was
thereaer used as the excitation wavelength for each protein.2648 | Food Funct., 2014, 5, 2646–2655Changes in maximum emission were compared between
proteins in a semi-quantitative manner and changes in the
emission spectra due to pre-treatment were also compared
qualitatively. Near UV Circular Dichroism spectra of 1.5 g L1
protein and far UV Circular Dichroism spectra of 0.2 g L1
protein were recorded in a 0.5 cm and 0.02 cm path length
quartz cuvette, respectively, using a Jasco J-810 spec-
tropolarimeter.35 The UniProt database was used to identify
structures, sequences and drug binding location on the BSA
molecule (http://www.uniprot.org/uniprot/P02769).Statistical analysis
All combinations of oxidative damage and glycation drivers
were tested as six true replicates, according to the experiment.
Assays were conducted in duplicate. Diﬀerences in fructos-
amine production between hydrogen peroxide levels were tested
using a one-way ANOVA and Tukey's post-hoc tests, at each
glucose level separately. The interaction between glucose levels
and hydrogen peroxide levels, as well as the overall dose
response eﬀect, was studied using two-way ANOVA. Statistical
analysis was performed using SPSS statistical soware package
version 19.0.0 (IBM, SPSS Soware, Armonk, NY, USA).Results
Using the primary search terms, 436 papers were identied,
with 40 excluded as duplicate entries. Titles from the remaining
396 articles were screened and 43 were excluded as not relevant
to the topic of the review (mostly studies focusing on phenyl-
alanine and other phenol ring-containing substances). During
abstract screening, 246 reports were excluded from the analysis
with the majority being in vitro or animal studies' reports,
alongside with reports from cross-sectional studies. Review
papers, conference proceedings, and reports written in
languages other than English were also excluded. A total of 107
full papers were screened, leading to the exclusion of 28 addi-
tional reports. These reports either performed a qualitative
analysis of metabolites in plasma or did not provide data on the
concentrations of the metabolites measured in plasma. The
reference list of each publication was screened in order to
identify other publications from the same study, in case the
data on the metabolite concentrations were published else-
where. Finally, two reports36,37 were excluded as phenolic acids
were reported as relative concentrations rather than absolute
(Fig. 2).
A total of 79 published studies satised the inclusion criteria
and reported plasma levels of polyphenol and polyphenol
metabolites following a dietary intervention. From those, 9
reports focused on longer-term feeding studies while the rest
covered acute changes in polyphenol levels following a single
consumption of a test food (Fig. 1). Acute trials mainly focused
on polyphenol bioavailability in the 5–24 hour window
following ingestion, while longer-term feeding studies investi-
gated changes in polyphenol metabolite levels aer 5 days to 8
weeks supplementations38,39 (Table 1).This journal is © The Royal Society of Chemistry 2014
Table 1 Evidence table of long-term supplementation trials measuring phenolic acids in plasma
Authors Food Study design Duration Metabolites Hydrolysis Comments
Heinrich et al.
(2013)
Blue honeysuckle
berry (165 grams per
day)
Uncontrolled (n ¼ 10) 1 week Below limit No Low
polyphenol
diet
throughout
Henning et al.
(2013)
Black tea (6 cups per
day)
Non-blinded RCT,
parallel (n ¼ 46)
3–6 weeks 3-Hydroxyphenylacetic acid:
261 mM
Yes No dietary
info
4-Hydroxyphenylacetic acid:
668 mM
3,4-Dihydroxyphenylacetic
acid: 117 mM
Hippuric acid: 2305 mM
Homovanillic acid: 176 mM
Henning et al.
(2013)
Green tea (6 cups per
day)
Non-blinded RCT,
parallel (n ¼ 47)
3–6 weeks 3-Hydroxyphenylacetic acid:
338 mM
Yes No dietary
info
4-hydroxyphenylacetic acid:
798 mM
3,4-Di hydroxyphenylacetic
acid: 135 mM
Hippuric acid: 1950 mM
Homovanillic acid: 199 mM
Oliveras-Lopez
et al. (2012)
Extra virgin olive oil as
a fat replacement plus
50 mL raw
Non-blinded cross over
(n ¼ 20)
4 weeks Hydroxytyrosol: 487 nM No Habitual diet
as control
Karlsen et al.
(2010)
Bilberry juice (1 L
diluted in water)
Non-blinded parallel
RCT (n ¼ 63)
4 weeks Quercetin: 43.6 nM Yes 3 weeks low
antioxidant/
berry diet
m-Coumaric: 12.8 nM
p-Coumaric: 27.4 nM
Protocatechuic: 99.4 nM
Kempf et al.
(2010)
Coﬀee 4 or 8 cups per
day (150 mL)
Single blind cross over
(n ¼ 47)
30 days 4 cups Yes No wash out,
all subjects
consumed
0 cups (1st
month), 4
cups (2nd
month), 8
cups (3rd
month)
Caﬀeic acid: 38.3 mM
Dihydrocaﬀeic acid: 47.9 nM
m-Coumaric acid: 26.4 nM
Dihydro-3-coumaric: 716 nM
Ferulic: 55.1 nM
Isoferulic: 23.5 nM
Dihydroferulic: 93.9 nM
Dihydroisoferulic: 56.5 nM
Dimethoxycinnamic: 77 nM
3-(3,4-Dimethoxyphenyl)-
propionic: 203 nM
8 cups
Caﬀeic acid: 62.2 mM
Dihydrocaﬀeic acid: 75.2 nM
m-Coumaric acid: 58.8 nM
Dihydro-3-coumaric: 1583 nM
Ferulic: 67.1 nM
Isoferulic: 49.8 nM
Dihydroferulic: 194.7 nM
Dihydroisoferulic: 90.6 nM
Dimethoxycinnamic: 177.7 nM
3-(3,4-Dimethoxyphenyl)-
propionic: 398 nM
Koli et al. (2010) 100 g bilberries and
nectar containing 50 g
lingonberries/100 g
black-currant-
strawberry puree (80%
black currant)
Non blinded RCT,
parallel (n ¼ 72)
8 weeks Quercetin: 40 nM Yes The two
supplements
were
consumed on
an alternate
day basis
Caﬀeic acid: 100 nM
Protocatechuic acid: 120 nM
p-Coumaric: 15 nM
Vanillic: 70 nM
3-(3-Hydroxyphenyl)-
propionic: 800 nM
3-Hydroxyphenylacetic: 275
nM
Homovanillic: 90 nM
3,4-Dihydroxyphenylacetic
acid: 140 nM
This journal is © The Royal Society of Chemistry 2014 Food Funct., 2014, 5, 2646–2655 | 2649
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Table 1 (Contd. )
Authors Food Study design Duration Metabolites Hydrolysis Comments
Urpi-Sarda et al.
(2009)
Cocoa powder 40
grams per day with 500
mL skimmed milk
Non-blinded RCT cross-
over (n ¼ 42)
4 weeks 3,4-Dihydroxyphenylpropionic
acid: 0.2 mM
Yes No wash-out
3-Hydroxyphenylpropionic
acid: 0.23 mM
3,4-Dihydroxyphenylacetic
acid: 0.11 mM
3-Hydroxyphenylacetic acid:
0.12 mM
Phenylacetic acid: 20.32 mM
p-Coumaric acid: 0.03 mM
Caﬀeic acid: 0.08 mM
Ferulic acid: 0.21 mM
Protocatechuic acid: 10.52 mM
Vanillic acid: 2.71 mM
4-Hydroxybenzoic acid: 9.73
mM
4-Hydroxyhippuric acid: 0.11
mM
3-Hydroxyhippuric acid: 0.48
mM
Grimm et al.
(2006)
Pine bark extract (200
milligrams per day)
Non-controlled (n ¼ 5) 5 days Catechin: 170 nM Yes Measured 4 h
aer the last
dose
Caﬀeic acid: 13.4 nM
Ferulic acid: 103 nM
Boyle et al. (2000) Rutin supplement (500
milligrams per day)
Double blind RCT
parallel (n ¼ 16)
6 weeks Quercetin: 166 nM Yes Record
avonoid
rich food
Kaempferol: 5.24 nM
Isorhamnetin: 9.49 nM
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View Article OnlineMost studies (Table 1) focused on a single food product,
from a diverse range including tea (black and green),40 coﬀee,41
olive oil,42 cocoa43 and berries, either as a juice44 or a mixed
berry diet.39 Two studies used extracts instead of a food
product.38,45 Regarding sample treatment prior to phenolic
acids' measurements, only two of the studies measured free
phenolic acids (i.e. without employing a prior hydrolysis step to
derive aglycones from glucuronide and sulfate esters).42,46 One
of these two studies did not detect suﬃcient phenolic acids in
plasma for quantication, despite using a HPLC/MS (LCQ Fleet
quadripole ion-trap MS) detection system,46 and the other
focused on hydroxytyrosol as a marker of compliance (olive oil
intake).42
The major phenolic acids identied in the studies were:
3-hydroxyphenylacetic acid (120 nM to 338 mM), 3,4-dihydroxy-
phenylacetic acid (110 nM to 135 mM), homovanillic acid (90 nM
to 199 mM), m-coumaric acid (12.8–58.8 nM), p-coumaric acid
(15–30 nM), caﬀeic acid (13.4 nM to 62.2 mM), protocatechuic
acid (99.4 nM to 10.52 mM), ferulic acid (55.1–210 nM) and
vanillic acid (70 nM to 2.71 mM). The compounds measured and
identied all represent concentrations of aglycones aer
hydrolysis and not concentrations of free compounds.
A combination of 3-hydroxyphenylacetic acid (160 nM), 3,4-
dihydroxyphenylacetic acid (40 nM), vanillic acid (20 nM), p-
coumaric acid (10 nM), caﬀeic acid (10 nM) and protocatechuic
acid (40 nM) was selected for the in vitro glycation of BSA. These
phenolic acids represent only a selection of all the acids iden-
tied in plasma aer feeding interventions, but they are the
ones for which data on absorption and metabolism are more2650 | Food Funct., 2014, 5, 2646–2655extensive. The glucuronidation of polyphenols and phenolic
acids may impact on the antiglycative capacity of the mole-
cules.13 These concentrations take into consideration the fact
that phenolic acid levels in all studies in the literature review
were measured aer hydrolysis, therefore a factor was applied
to estimate what percentage of the reported values would be
true for non-conjugated phenolic acids.
This percentage was calculated based on ndings from
previous studies and more specically, data from acute feeding
interventions identied during the process of the present
literature review. From acute feeding interventions measuring
both the conjugated and non-conjugated form of phenolic
acids, only 20–26% of the total caﬀeic found in plasma aer
coﬀee consumption is in free form.47,48 Similarly only 25% of the
total vanillic acid, 40–50% of the total p-coumaric acid and 15–
25% of the total ferulic acid are found as free phenolic acids.48,49
In contrast 4-hydroxyphenylacetic acid is less extensively
metabolised (80% present as free form).49
The published reports were of variable methodological
quality. Although the detection systems used for phenolic acids'
measurement were based on mass spectrometry (MS, MS/MS,
quadripole MS), some studies used less sensitive detection
systems like ultraviolet, uorimetric and electrochemical
detectors.38,41,45 One of the major methodological limitations
was that 7 out of 9 studies employed some form of hydrolysis
prior to phenolic acids' determination. The measurement of
aglycones following hydrolysis leads to a signicant increase in
the concentrations reported. The only study measuring
phenolic acid concentrations without hydrolysis did not detectThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineconcentrations high enough for quantication even with a
sensitive quadripole MS system.46
The variable duration and dose of the compounds tested also
make comparisons between the studies available diﬃcult. The
compounds tested were delivered in various matrices, some as
supplements,38,45 others as drinks,41,43,50,51 or whole foods46 and
even as dietary patterns (combination of various food items).39
Suchmatrices will have a signicant eﬀect on bioavailability and
potential long-term changes in absorption through changes in
gut microbiota cannot be excluded/controlled for. The lack of
successful control conditions is another point to be mentioned,
as some studies either hadno control groups or used a cross-over
design without allowing for suﬃcient wash-out periods.38,41,43
When bioavailability of (poly)phenolic compounds is the main
focus of the study the lack of a control group may be of lesser
importance but not allowing for suﬃcient wash-out periods can
introduce a carry-over eﬀect between the interventionsmaking it
diﬃcult to compare between doses/groups tested.
Finally, as (poly)phenolic compounds are nearly ubiquitous,
controlling the eﬀect of the background diet is important when
studying bioavailability. In the studies reviewed, the back-
ground diet control was variable ranging from the subjects
being requested to abstain from polyphenol sources throughout
the experimental period46,51 to being asked to consume their
habitual diet.42 One study requested from the participants to
avoid food products similar to those provided during the study
period39 and another gave no advice but requested from the
participants to keep records of the avonoid rich foods
consumed during the study.45 In order to control the eﬀect of
background diet, Grimm et al. requested their volunteers to
follow a avonoid free diet 24 hours prior to blood sampling.38
Unfortunately three of the studies did not provide any infor-
mation on whether and how they attempted to control the eﬀect
of the background diet.41,43,50 In this instance lack of adequate
control of the background diet was not considered as a bias
given the purpose of the review.In vitro assessment of antiglycative capacity of phenolic acids
The antiglycative capacity of phenolic acids was investigated in
a two dimensional design. Phenolic acids were tested for theirTable 2 Fructosamine concentration (mM DMF equivalent) after two we
Glucose level (mM)
Pre-treatment
Native mean (SD)
0 0.22 (0.01)
5 0.29 (0.01)
10 0.36 (0.02)
0 + H2O2 (10 nM) 0.19 (0.04)
5 + H2O2 (10 nM) 0.32 (0.03)
10 + H2O2 (10 nM) 0.40 (0.03)
0 + phenolic acids 0.22 (0.01)
5 + phenolic acids 0.31 (0.02)
10 + phenolic acids 0.38 (0.04)
a p < 0.05 vs native.
This journal is © The Royal Society of Chemistry 2014capacity to reduce fructosamine production when (i) added in
the reaction solution alongside glucose and H2O2 and (ii) when
pre-incubated with albumin (BSA) prior to the glycation
incubation.Eﬀect of addition of hydrogen peroxide and phenolic acids in
the reaction solution
Addition of 10 nM H2O2 in the reaction solution throughout the
incubation has a signicant but opposing impact on fructos-
amine production of both native and phenolic pre-incubated
albumin. Incubation of native albumin in the presence of H2O2
led to signicantly higher levels of fructosamine at 10 mM
glucose compared to the glucose-only control (11% increase),
whereas a reduction in fructosamine production was seen in the
phenolic pre-incubated albumin (Table 2). A two-way ANOVA
analysis showed that H2O2 aﬀects fructosamine production of
native and phenolic pre-incubated albumin independently of
glucose (p < 0.001 for both albumin forms; H2O2 plus glucose vs.
glucose only control).
In contrast addition of phenolic acids in the reaction solu-
tion throughout the incubation period had no signicant eﬀect
on fructosamine production compared to glucose alone in any
of the three albumin forms used (Table 2).Eﬀect of protein pre-treatment
Pre-oxidised and phenolic-pre-incubated albumin were more
prone to glycation than the native molecule in the presence of
10 mM glucose (p ¼ 0.001 and p ¼ 0.02, respectively) (Table 2).
This eﬀect was independent of the glucose concentration, for
both the pre-oxidised and the phenolic-pre-incubated albumin
(p¼ 0.001, two-way ANOVA). In the presence of H2O2, native and
pre-oxidised albumin showed similar glycation levels (p ¼ 0.52;
two-way ANOVA).
Pre-incubation with phenolic acids, on the other hand,
signicantly reduced glycation in the presence of H2O2 (p ¼
0.001 vs. native; two-way ANOVA). This eﬀect was seen at both 5
and 10 mM glucose (p ¼ 0.01 and p < 0.001, respectively, vs.
native albumin) (Fig. 3) and the glycation reduction was greater
with increasing glucose levels (p < 0.001 for the interaction pre-
treatment* glucose levels).eks incubation with hydrogen peroxide or phenolic acids
Pre-oxidised mean (SD)
Phenolic-rich
mean (SD)
0.23 (0.02) 0.23 (0.02)
0.32 (0.01) 0.32 (0.02)
0.41 (0.03)a 0.40 (0.03)a
0.20 (0.02) 0.23 (0.01)
0.31 (0.03) 0.28 (0.02)a
0.40 (0.04) 0.31 (0.03)a
0.22 (0.02) 0.22 (0.01)
0.30 (0.02) 0.29 (0.02)
0.38 (0.03) 0.36 (0.03)
Food Funct., 2014, 5, 2646–2655 | 2651
Fig. 3 Fructosamine concentration (mM DMF equivalent) after two
weeks incubation in the presence of glucose and H2O2 (10 nM) for
native, pre-oxidised and phenolic-pre-incubated BSA (PP-BSA). Two-
way ANOVA analysis showed a signiﬁcant eﬀect of phenolic-pre-
incubation inhibiting glycation.*p < 0.05.
Fig. 5 Near UV Circular Dichroism spectra of 1.5 mg mL1 of native
BSA (blue), oxidised BSA (green) and phenolic-treated BSA (red).
Spectra were recorded in a 0.5 cm path length quartz cuvette using a
Jasco J-810 spectropolarimeter.
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View Article OnlineEﬀect on AGE production
Aer two weeks incubation, AGE levels were not higher under
any experimental conditions compared to the 0 mM glucose
control, but for oxidised BSA exposed to 10 mM glucose with
10 nM H2O2 (p ¼ 0.048, 205  15.8 vs. 284  76.1 AU; ox-BSA
0 mM glucose plus 10 nM H2O2 vs. ox-BSA 10 mM glucose plus
10 nM H2O2).Eﬀect of protein pre-treatment on protein structure and
characteristics
The circular dichroism (CD) analysis showed no eﬀect of the
pre-treatment on the secondary protein structure (Fig. 5 & 6).
However, exposure to 10 nM H2O2 for 8 h leads to a 25%
decrease in tryptophan uorescence. Pre-incubation with
phenolic acids for 8 h resulted in a 38% reduction, indicative of
protein–phenolic acid binding (Fig. 4).Fig. 6 Far UV Circular Dichroism spectra of 0.2 mgmL1 of native BSA
(blue), oxidised BSA (green) and phenolic-treated BSA (red). Spectra
were recorded in a 0.02 cm path length quartz cuvette using a Jasco
J-810 spectropolarimeter.Discussion
Our mechanistic study results indicate that pre-treatment of
albumin with phenolic acids inhibits fructosamine production,
especially in the presence of oxidative stress or oxidative
damage. This antiglycative activity was apparent when
comparing the glycation achieved using phenolic-enriched
albumin to those with the native and pre-oxidised BSA. A two-Fig. 4 Emission spectra of 0.2 g L1 BSA, ox-BSA and PP-BSA at l ¼
277 nm showing the quenching eﬀect of protein pre-treatment.
Spectra were recorded at pH 7.4.
2652 | Food Funct., 2014, 5, 2646–2655way ANOVA analysis showed that, in the presence of H2O2,
albumin pre-incubated with phenolic acids had a signicantly
lower fructosamine content compared to the native BSA and the
pre-oxidised BSA molecule. Phenolic acid pre-incubation only
oﬀered protection against fructosamine production in the
presence of H2O2 10 nM: it provided no protection against gly-
cation by glucose alone. In the presence of H2O2, the anti-
glycative activity of phenolic acid pre-incubation was greater
with higher glucose levels (10% vs. 22.5% decrease at 5 and
10 mM glucose, respectively). No eﬀect was seen for AGE
production, with the exception of pre-oxidised BSA exposed to a
combination of 10 nM H2O2 and 10 mM glucose. This may be
due to the duration of the experiment, too short to lead to AGEThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineformation in the given glucose concentrations. In contrast with
most of the literature to date, which suggests that polyphenols
and phenolic acids added to the incubation solution provide
potent antiglycative activity,14,18,24,52,53 our results show that
physical protection from glycation through protein–phenolic
acid interaction is the most likely antiglycative mechanism
especially in oxidative environments. In the previous investi-
gation, concentrations used were non-physiological, with the
lowest glucose concentration being 30 mM (>5–6 fold higher
than normoglycaemia), generating higher glycation than our
use of physiologically relevant 5 and 10 mM concentrations,
representative of normoglycaemic and diabetic conditions,
respectively.11 Our results suggest that pre-incubation of
albumin with phenolic acids is the most likely mechanism to
oﬀer protection against glycation in a physiologically relevant
system. Pre-incubation of BSA with either 10 nM H2O2 or
phenolic acids did not aﬀect the secondary structure of the
molecule but both led to the reduction of tryptophan uores-
cence. Tryptophan is an established oxidation target in the BSA
molecule,54 and oxidation would modify its uorescence. The
BSA molecule has only two tryptophans: one inside a a-helix in
domain I and another one inside the hydrophobic binding
pocket of domain II.55,56 A proposed mechanism of action from
our result involves steric hindrance, with phenolic acids
binding in a BSA locum which includes a tryptophan and
consequently preventing the amino acids in this locum to
participate in oxidation and subsequent glycation reactions
(since BSA oxidation increases its susceptibility to glycation).11
The literature review highlighted that 3-hydroxyphenylacetic
acid, 3,4-dihydroxyphenylacetic acid, homovanillic acid, m-
coumaric acid, p-coumaric acid, caﬀeic acid, protocatechuic
acid, ferulic acid and vanillic acid are most commonly detected
in plasma aer long-term feeding interventions. Concentra-
tions of phenolic acids ranged between 13.4 nM and 338.0 mM.
The majority of the studies measured phenolic acid levels as
aglycones aer hydrolysis of conjugated phenolic acids. This
could have led towards a systematic overestimation of phenolic
acid levels. Phenolic acids are subject to extensive rapid
metabolism22,27 and since the chemical properties of their
conjugates are oen diﬀerent, even opposite, from those of the
aglycones13 it is important for in vitro studies to take their
relative abundance into consideration. More in vivo studies,
reporting phenolic acid levels as aglycones and conjugates
separately, are needed.
Nonetheless, the results of the literature review showcase
that the use of food extracts or food-derived polyphenol mole-
cules in mechanistic studies focusing on human metabolism is
likely to be of limited physiological relevance. The parent
compounds commonly used for in vitro studies are rarely found
in circulation, while metabolites like phenolic acids are found
in potentially important concentrations in the nM to mM range.
These metabolites are also not seen in isolation, but in fairly
consistent combinations of phenylacetic acids, caﬀeic acid,
vanillic acid and protocatechuic acid.
Despite increasing evidence that a very limited fraction of
dietary polyphenols are absorbed, with low levels of metabolites
circulating for a limited amount of time, in vitromodels to-dateThis journal is © The Royal Society of Chemistry 2014utilise designs that make them irrelevant to physiology outside
the gut lumen.30,57–59 Most of these reports used supra-physio-
logical glucose and albumin concentrations30,57,59 as well as
methanolic extracts of food products.60–62 While of importance
for the food industry,63 they hold limited translational value for
human health and may confuse our understanding of the role
of glycation in health and disease. Here, a combination of caf-
feic acid, p-coumaric acid, vanillic acid, protocatechuic acid, 3-
hydroxyphenyl acetic acid, and 3,4-dihydroxyphenyl acetic acid
was chosen to replicate physiological conditions, according to
the systematic review.
This study has several limitations. The in vitro design is in
itself limiting and translation to physiology must still be
cautious. Concentrations were chosen to mimic physiology for
glucose, H2O2, and phenolic acids but this made it impossible
to draw conclusions on the eﬀect of individual phenolic acid on
glycation. Not all our results t a simple mechanistic explana-
tion. It is intriguing that our results suggest that phenolic-pre-
incubated albumin was more prone to glycation than native
albumin, in the presence of 10 mM glucose. We can oﬀer no
plausible mechanism to explain this, which may have been a
random or chance eﬀect. Nonetheless, this study provides
evidence to extend the published literature, and shows that
research into the antiglycative capacity of phenolics using
physiological concentrations (for both phenolics and glucose) is
achievable and desirable.Conclusions
Phenolic acids have the capacity to modulate early stages of
protein glycation under normoglycaemic, physiologically rele-
vant conditions. Incubation with phenolic acids prior to glyca-
tion signicantly inhibits the process in the presence of
oxidative stress. Designing in vitro studies with a high degree of
physiological relevance is very important in order to reach
biologically sound conclusions.Acknowledgements
AV is in receipt of a Yorkhill Children Charity PhD scholarship.
The authors express their appreciation for the CD spectroscopy
analysis to Dr Sharon Kelly. They would also like to thank Dr
Stuart Caldwell, Dr Richard C. Hartley and Prof. Graeme Cooke
for the help in the tryptophan uorescence analysis.References
1 C. Sabanayagam, G. Liew, E. S. Tai, A. Shankar, S. C. Lim,
T. Subramaniam and T. Y. Wong, Diabetologia, 2009, 52,
1279–1289.
2 S. F. Yan, R. Ramasamy, Y. Naka and A. M. Schmidt, Circ.
Res., 2003, 93, 1159–1169.
3 J. W. Baynes, Ann. N. Y. Acad. Sci., 2002, 959, 360–367.
4 P. J. Thornalley, Biochem. Soc. Trans., 2003, 31, 1341–1342.
5 A. American Diabetes, Diabetes Care, 2011, 34(suppl. 1), S62–
S69.Food Funct., 2014, 5, 2646–2655 | 2653
Food & Function Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
A
ug
us
t 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
0/
02
/2
01
5 
14
:3
0:
39
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online6 N. Shaklai, R. L. Garlick and H. F. Bunn, J. Biol. Chem., 1984,
259, 3812–3817.
7 E. Selvin, M. W. Steﬀes, C. M. Ballantyne, R. C. Hoogeveen,
J. Coresh and F. L. Brancati, Ann. Intern. Med., 2011, 154,
303–309.
8 E. Selvin, M. W. Steﬀes, H. Zhu, K. Matsushita,
L. Wagenknecht, J. Pankow, J. Coresh and F. L. Brancati,
N. Engl. J. Med., 2010, 362, 800–811.
9 E. L. Barr, E. J. Boyko, P. Z. Zimmet, R. Wolfe, A. M. Tonkin
and J. E. Shaw, Diabetologia, 2009, 52, 415–424.
10 E. Selvin, J. Coresh, E. Shahar, L. Zhang, M. Steﬀes and
A. R. Sharrett, Lancet Neurol., 2005, 4, 821–826.
11 A. Vlassopoulos, M. E. Lean and E. Combet, Free Radical Biol.
Med., 2013, 60, 318–324.
12 J. Venkatraman, K. Aggarwal and P. Balaram, Chem. Biol.,
2001, 8, 611–625.
13 Y. Xie and X. Chen, Curr. Drug Metab., 2013, 14, 414–431.
14 H. Y. Kim and K. Kim, J. Agric. Food Chem., 2003, 51, 1586–
1591.
15 T. H. Hou, J. P. Chung, S. S. Chen and T. L. Chang, Food Sci.
Biotechnol., 2013, 22, 839–844.
16 J. W. Wu, C. L. Hsieh, H. Y. Wang and H. Y. Chen, Food
Chem., 2009, 113, 78–84.
17 W. Sompong, A. Meeprom, H. Cheng and S. Adisakwattana,
Molecules, 2013, 18, 13886–13903.
18 C. H. Wu and G. C. Yen, J. Agric. Food Chem., 2005, 53, 3167–
3173.
19 J. B. Xiao and G. Y. Kai, Crit. Rev. Food Sci. Nutr., 2012, 52, 85–
101.
20 E. Verzelloni, D. Tagliazucchi, D. Del Rio, L. Calani and
A. Conte, Food Chem., 2011, 124, 1430–1435.
21 X. Zhang, F. Chen and M. Wang, J. Agric. Food Chem., 2014,
62, 1643–1648.
22 A. Scalbert, C. Morand, C. Manach and C. Re´me´sy, Biomed.
Pharmacother., 2002, 56, 276–282.
23 C. Manach, G. Williamson, C. Morand, A. Scalbert and
C. Remesy, Am. J. Clin. Nutr., 2005, 81, 230S–242S.
24 T. Nagasawa, N. Tabata, Y. Ito, N. Nishizawa, Y. Aiba and
D. D. Kitts, Mol. Cell. Biochem., 2003, 249, 3–10.
25 G. Williamson and C. Manach, Am. J. Clin. Nutr., 2005, 81,
243s–255s.
26 A. Crozier, I. B. Jaganath and M. N. Cliﬀord, Nat. Prod. Rep.,
2009, 26, 1001–1043.
27 A. Scalbert and G. Williamson, J. Nutr., 2000, 130, 2073s–
2085s.
28 C. Manach, A. Scalbert, C. Morand, C. Remesy and
L. Jimenez, Am. J. Clin. Nutr., 2004, 79, 727–747.
29 P. Vitaglione, G. Donnarumma, A. Napolitano, F. Galvano,
A. Gallo, L. Scal and V. Fogliano, J. Nutr., 2007, 137,
2043–2048.
30 C. Harris, A. Cuerrier, E. Lamont, P. Haddad, J. Arnason,
S. L. Bennett and T. Johns, Plant Foods Hum. Nutr., 2014,
69, 71–77.
31 A. Crozier, I. B. Jaganath and M. N. Cliﬀord, Nat. Prod. Rep.,
2009, 26, 1001–1043.2654 | Food Funct., 2014, 5, 2646–265532 M. Serani, M. F. Testa, D. Villan˜o, M. Pecorari, K. van
Wieren, E. Azzini, A. Brambilla and G. Maiani, Free Radical
Biol. Med., 2009, 46, 769–774.
33 W. Mullen, M.-A. Archeveque, C. A. Edwards, H. Matsumoto
and A. Crozier, J. Agric. Food Chem., 2008, 56, 11157–11164.
34 J. R. Baker, D. V. Zyzak, S. R. Thorpe and J. W. Baynes, Clin.
Chem., 1993, 39, 2460–2465.
35 S. M. Kelly, T. J. Jess and N. C. Price, Biochim. Biophys. Acta,
2005, 1751, 119–139.
36 D. C. Nieman, N. D. Gillitt, A. M. Knab, R. A. Shanely,
K. L. Pappan, F. Jin andM. A. Lila, PLoS One, 2013, 8, e72215.
37 B. A. Stracke, C. E. Ruefer, A. Bub, S. Seifert, F. P. Weibel,
C. Kunz and B. Watzl, Eur. J. Nutr., 2010, 49, 301–310.
38 T. Grimm, R. Skrabala, Z. Chovanova, J. Muchova,
K. Sumegova, A. Liptakova, Z. Durackova and P. Hogger,
BMC Clin. Pharmacol., 2006, 6, 4.
39 R. Koli, I. Erlund, A. Jula, J. Marniemi, P. Mattila and
G. Alhan, J. Agric. Food Chem., 2010, 58, 3927–3932.
40 S. M. Henning, P. Wang, N. Abgaryan, R. Vicinanza, D. M. de
Oliveira, Y. Zhang, R.-P. Lee, C. L. Carpenter, W. J. Aronson
and D. Heber, Mol. Nutr. Food Res., 2013, 57, 483–492.
41 K. Kempf, C. Herder, I. Erlund, H. Kolb, S. Martin,
M. Carstensen, W. Koenig, J. Sundvall, S. Bidel, S. Kuha
and J. Tuomilehto, Am. J. Clin. Nutr., 2010, 91, 950–957.
42 M.-J. Oliveras-Lopez, M. Innocenti, F. Martin Bermudo,
H. Lopez-Garcia de la Serrana and N. Mulinacci, Eur. J.
Lipid Sci. Technol., 2012, 114, 999–1006.
43 M. Urpi-Sarda, M. Monagas, N. Khan, R. Llorach, R. Ma
Lamuela-Raventos, O. Jauregui, R. Estruch, M. Izquierdo-
Pulido and C. Andres-Lacueva, J. Chromatogr. A, 2009,
1216, 7258–7267.
44 A. Karlsen, I. Paur, S. Bøhn, A. Sakhi, G. Borge, M. Serani,
I. Erlund, P. Laake, S. Tonstad and R. Blomhoﬀ, Eur. J.
Nutr., 2010, 49, 345–355.
45 S. P. Boyle, V. L. Dobson, S. J. Duthie, D. C. Hinselwood,
J. A. M. Kyle and A. R. Collins, Eur. J. Clin. Nutr., 2000, 54,
774–782.
46 J. Heinrich, K. Valentova, J. Vacek, I. Palikova,
M. Zatloukalova, P. Kosina, J. Ulrichova, J. Vrbkova and
V. Simanek, J. Agric. Food Chem., 2013, 61, 4526–4532.
47 M. Nardini, E. Cirillo, F. Natella and C. Scaccini, J. Agric. Food
Chem., 2002, 50, 5735–5741.
48 M. Nardini, M. Forte, U. Vrhovsek, F. Mattivi, R. Viola and
C. Scaccini, J. Agric. Food Chem., 2009, 57, 2711–2718.
49 M. Nardini, F. Natella, C. Scaccini and A. Ghiselli, J. Nutr.
Biochem., 2006, 17, 14–22.
50 S. M. Henning, P. W. Wang, N. Abgaryan, R. Vicinanza,
D. M. de Oliveira, Y. J. Zhang, R. P. Lee, C. L. Carpenter,
W. J. Aronson and D. Heber, Mol. Nutr. Food Res., 2013, 57,
483–492.
51 A. Karlsen, I. Paur, S. K. Bohn, A. K. Sakhi, G. I. Borge,
M. Serani, I. Erlund, P. Laake, S. Tonstad and
R. Blomhoﬀ, Eur. J. Nutr., 2010, 49, 345–355.
52 N. Lunceford and A. Gugliucci, Fitoterapia, 2005, 76, 419–
427.
53 I. Bousova, J. Martin, L. Jahodar, J. Dusek, V. Palicka and
J. Drsata, J. Pharm. Biomed. Anal., 2005, 37, 957–962.This journal is © The Royal Society of Chemistry 2014
Paper Food & Function
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
A
ug
us
t 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
0/
02
/2
01
5 
14
:3
0:
39
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online54 S. Guedes, R. Vitorino, R. Domingues, F. Amado and
P. Domingues, Rapid Commun. Mass Spectrom., 2009, 23,
2307–2315.
55 K. A. Majorek, P. J. Porebski, A. Dayal, M. D. Zimmerman,
K. Jablonska, A. J. Stewart, M. Chruszcz and W. Minor,
Mol. Immunol., 2012, 52, 174–182.
56 N. Tayeh, T. Rungassamy and J. R. Albani, J. Pharm. Biomed.
Anal., 2009, 50, 107–116.
57 W. Daiponmak, C. Senakun and S. Siriamornpun, Int. J. Food
Sci. Technol., 2014, 49, 1805–1810.
58 H. Ito, P. Li, M. Koreishi, A. Nagatomo, N. Nishida and
T. Yoshida, Food Chem., 2014, 152, 323–330.This journal is © The Royal Society of Chemistry 201459 P. G. Dorsey and P. Greenspan, J. Med. Food, 2014, 17, 447–
454.
60 S.-C. Ho, P.-W. Chang, H.-T. Tong and P.-Y. Yu, Int. J. Food
Prop., 2013, 17, 617–628.
61 G. Cervato, M. Carabelli, S. Gervasio, A. Cittera, R. Cazzola
and B. Cestaro, J. Food Biochem., 2000, 24, 453–465.
62 P. Hegde, G. Chandrakasan and T. Chandra, J. Nutr.
Biochem., 2002, 13, 517.
63 X. Zhang, F. Chen and M. Wang, J. Agric. Food Chem., 2014,
62, 1643–1648.Food Funct., 2014, 5, 2646–2655 | 2655
